Hydroxyurea (PV / ET high-risk 1L cytoreduction) + baseline phlebotomy/ASA

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-HYDROXYUREA` `DRUG-ASPIRIN`

ID	`REG-HU-PV-ET`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-MPN-2015` `SRC-NCCN-MPN-2025` `SRC-RESPONSE-VANNUCCHI-2015`

Notes

Standard 1L cytoreduction for high-risk PV (age >60 OR prior thrombosis) AND high-risk ET (same criteria). Targets: - PV: Hct <45% (mainstay; CYTO-PV trial), platelets <400K - ET: platelets <400-450K Phlebotomy is the foundation in PV (with HU layered for cytoreduction); ASA at low dose unless contraindicated (extreme thrombocytosis with acquired vWD = relative contraindication). STUB — requires clinical co-lead signoff before publication.

Used By

Indication

IND-ET-1L-ASA - IND-ET-1L-ASA
IND-ET-1L-HU - IND-ET-1L-HU
IND-PV-1L-HU - IND-PV-1L-HU
IND-PV-1L-PHLEBOTOMY-ASA - IND-PV-1L-PHLEBOTOMY-ASA